___
Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord 2014; 2:15. [CrossRef]
Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65:432-441. [CrossRef]
Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DAUG-6). Bipolar Disord 2010; 12:483- 493. [CrossRef]
Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B; Trail 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011; 72:1452-1464. [CrossRef]
Karanti A, Kardell M, Lundberg U, Landen M. Changes in mood stabilizer prescription patterns in bipolar disorder. J Affect Disord 2016; 195:50-56. [CrossRef]
Kessing LV, Vradi E, Anderson PK. Nationwide and population- based prescription patterns in bipolar disorder. Bipolar Disord 2016; 18:174-182. [CrossRef]
Valenstein M, McCarthy JF, Austin KL, Greden JF, Young EA, Blow FC. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006; 163:1219-1225. [CrossRef]
Nolen WA. Show we prescribe lithium more often? Dusunen Adam: Journal of Psychiatry and Neurological Sciences 2016; 29:99-102. [CrossRef]
Bauer M, Gitlin M. The Essential Guide to Lithium Treatment. Springer, 2016. [CrossRef]
Jamison KR, Gerner RH, Goodwin FK. Patient and physician attitudes toward lithium: relationship to compliance. Arch Gen Psychiatry 1979; 36:866-869. [CrossRef]
Baldessarini RJ, Salvatore P, Khalsa HM, Gebre-Medhin P, Imaz H, González-Pinto A, Perez J, Cruz N, Maggini C, Tohen M. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord 2010; 12:264-270. [CrossRef]
Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261-269. [CrossRef]
Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12 month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162:1281-1290. [CrossRef]
BALANCE investigators and collaborators, Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, Morriss R, Alder N, Juszczak E. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trail. Lancet 2010; 375:385-395. [CrossRef]
Gitlin MJ. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord 2016; 4:27. [CrossRef]
Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry 1989; 50:127-131.
Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ. A randomized, placebo- controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex maintenance study group. Arch Gen Psychiatry 2000; 57:481-489. [CrossRef]
Nierenberg AA, McElroy SL, Friedman ES, Ketter TA, Shelton RC, Deckersbach T, McInnis MG, Bowden CL, Tohen M, Kocsis JH, Calabrese JR, Kinrys G, Bobo WV, Singh V, Kamali M, Kemp D, Brody B, Reilly-Harrington NA, Sylvia LG, Shesler LW, Bernstein EE, Schoenfeld D, Rabideau DJ, Leon AC, Faraone S, Thase ME. Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trail of lithium versus quetiapine for bipolar disorder. J Clin Psychiatry 2016; 77:90-99. [CrossRef]
Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23:723-733. [CrossRef]
Kleiner J, Altshuler L, Hendrick V, Hershman JM. Lithium- induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 1999; 60:249-255. [CrossRef]
Gitlin M. Lithium and the kidney: an updated review. Drug Saf 1999; 20:231-243. [CrossRef]
Azab AN, Shnaider A, Osher Y, Wang D, Bersudsky Y, Belmaker RH. Lithium nephrotoxicity. Int J Bipolar Disord 2015; 3:28. [CrossRef]
Kessing LV, Gerds TA, Feldt-Rasmussen B, Andersen PK, Licht RW. Lithium and renal and upper urinary tract tumors - results from a nationwide population-based study. Bipolar Disord 2015; 17:805-813. [CrossRef]
Aiff H, Attman PO, Aurell M, Bendez H, Schön S, Svedlund J. End-stage renal disease associated with prophylactic lithium treatment. Eur Neuropsychopharmacol 2014; 24:540-544. [CrossRef]
Aiff H, Attman P, Aurell M, Bendez H, Ramsauer B, Schön S, Svedlund J. Effects of 10 to 30 years of lithium treatment on kidney function. J Psychopharmacol 2015; 29:608-614. [CrossRef]
McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379:721-728. [CrossRef]
Shapiro HI, Davis KA. Hypercalcemia and "primary" hyperparathyroidism during lithium therapy. Am J Psych 2015; 172:12-15. [CrossRef]
Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology 2010; 62:43-49. [CrossRef]
Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346:f3646. [CrossRef]